FDA Grants Priority Review to Zanubrutinib for Relapsed/Refractory Mantle Cell Lymphoma

Zanubrutinib, a Bruton’s tyrosine kinase inhibitor, is being evaluated in a broad pivotal clinical program across multiple B-cell malignancies.
— Read on www.specialtypharmacytimes.com/

7 thoughts on “FDA Grants Priority Review to Zanubrutinib for Relapsed/Refractory Mantle Cell Lymphoma”

Leave a Reply

Your email address will not be published. Required fields are marked *